Medtronic (MDT) Reports 9.9% Q4 Revenue Growth, UBS Upgrades Stock
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowMedtronic (NYSE: MDT) announced Q4 revenue of $9.8 billion, reflecting a 9.9% increase, while fiscal 2026 revenue reached $36.4 billion, up 8.4%. The company achieved its highest annual revenue growth in 10 years, driven by significant performance in its cardiac segment, with Cardiac Ablation Solutions revenue increasing by 78%. UBS upgraded Medtronic from Neutral to Buy, citing signs of a turnaround after several years of underperformance. This information is important for investors as it indicates potential renewed growth and improved prospects for Medtronic, factoring into decisions on stock valuation and investment strategies.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Medtronic plc (MDT)
Medtronic is one of the world’s largest medical-device makers.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MDT news
- Medtronic Faces $88 Million Verdict in Hernia Mesh Trial
- Medtronic (MDT) Reports Highest Annual Revenue Growth in Decade
- Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
- Medtronic (MDT) Reports Strong Q4 with $36 Billion Revenue Growth
- Medtronic (MDT) Gains FDA Approval for New Robotic Surgery Platform
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
S&P 500 and Nasdaq Rise as AI Stocks Rebound Before Earnings
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18